NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and
how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and
ST-positive solid tumors. The main question it aims to answer is to find the recommended dose
and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly
doses of NEROFE and doxorubicin.